Scots-Knight Denise 4

What Happened
Denise Scots‑Knight, Chief Executive Officer of Mereo BioPharma Group plc (MREO), received three equity awards on February 1, 2026 totaling 1,860,000 derivative shares (1,035,000 + 345,000 + 480,000). Each grant is reported at $0.00 per share (no cash paid). The filing classifies these as awards/acquisitions of derivative securities (transaction code A)—i.e., equity compensation grants rather than open‑market purchases or sales.

Key Details

• Transaction date: February 1, 2026; Form 4 filed February 2, 2026 (timely).
• Reported price: $0.00 per share; total awarded = 1,860,000 derivative shares.
• Vesting notes from the filing:
  • F1: 25% vests Feb 1, 2027; remainder vests in equal monthly installments over the following three years.
  • F3: Some awards vest in substantially equal monthly installments over one year from the Feb 1, 2026 grant date.
  • F2: Each American Depositary Share (ADS) represents five ordinary shares (relevant if awards are reported or converted as ADS).
• The filing reports derivative awards (type not further specified in the excerpt); no exercise or sale occurred and there was no immediate cash exchange.
• Shares owned after the grants are not disclosed in the provided excerpt.

Context
These are executive compensation awards intended to vest over time (retention/performance incentives) and do not represent an immediate market purchase or sale. For retail investors, grants are common and signal management compensation/retention rather than an explicit buy or sell view — purchases are typically more informative about personal conviction.